Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, June 29 2021 - 22:47
AsiaNet
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
BRUSSELS and CASTRES, France, June 29, 2021 /PRNewswire-AsiaNet/ --

- Partnership builds on complementary strengths to advance research in melanoma 
with a focus on Stage 2 melanoma patients

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre 
Fabre today announced a strategic partnership in support of patients with 
resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, 
design and execution of a large Phase 3 study investigating the use of BRAF and 
MEK targeted therapies to reduce the risk of relapse in this patient 
population, currently under approval with authorities. 

"Sadly, still today too many patients with Stage 2 melanoma have their cancer 
come back, even after their tumour is removed. Further understanding how 
effective treatments can have an impact on recurrence is essential," said Dr 
Denis Lacombe, CEO of EORTC. "We are pleased to collaborate with Pierre Fabre 
who bring strong heritage and expertise in this therapeutic area, to make a 
true difference to people living with Stage 2 melanoma."

"Collaboration between Pierre Fabre and EORTC is the perfect match between our 
medical and clinical capabilities and a leading global network in oncology 
research. Our strong complementary expertise have potential to transform 
patient care in melanoma," said Dr Deborah Szafir, EVP, Head of Medical and 
Patient Centricity Division at Pierre Fabre. "Our strategic partnership on a 
pioneering Phase 3 study confirms Pierre Fabre's R&D commitment to oncology and 
particularly in skin cancers. Through our growing expertise in BRAF and MEK 
inhibitors, we aim to strengthen our support for patients with skin cancers."

Pierre Fabre has a long-standing commitment to the melanoma community and takes 
a unique holistic approach to skin health through combined expertise in 
oncology, dermatology, and dermo-cosmetics. EORTC, a network uniting 2,800 
clinical cancer research experts across the globe, shares Pierre Fabre's 
commitment to improving the standard of cancer treatment for patients. 

For further information, please visit the EORTC website (www.eortc.org) and the 
Pierre Fabre website (www.pierre-fabre.com) - @PierreFabre.

References

1. Neoplasma. 2016;63(4):510-7. doi: 10.4149/neo_2016_403.
2. American Cancer Society. What Causes Melanoma Skin Cancer. Available at: 
https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-prevention/what-causes.html. 
Accessed June 2021.
3. International Agency for Research on Cancer. Melanoma of skin. Available at: 
https://gco.iarc.fr/today/data/factsheets/cancers/16-Melanoma-of-skin-fact-sheet.pdf. 
Accessed June 2021.
4. Klein O, et al. Eur J Cancer 2013;49:1073–1079.
5. Melanoma UK. 2020 Melanoma Skin Cancer Report. Available at: 
https://www.melanomauk.org.uk/2020-melanoma-skin-cancer-report. Accessed June 
2021.

Logo - https://mma.prnewswire.com/media/1553958/EORTC_Pierre_Fabre_Logo.jpg

Contacts:

EORTC:
Isabelle Gautherot 
communication@eortc.org 

Pierre Fabre:
Anne Kerveillant 
anne.kerveillant@pierre-fabre.com

Source: EORTC and Pierre Fabre
Translations

Japanese